MétaCan
Menu
Back to cohort
Record W2809481277 · doi:10.18632/oncotarget.25345

Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma

2018· article· en· W2809481277 on OpenAlexafffundabout
Michelle Chadwick, Adam Lane, Dana Thomas, Amanda R. Smith, Angela R. White, Dominique Davidson, Yuxin Feng, Elisa Boscolo, Yi Zheng, Denise M. Adams, Anita Gupta, André Veillette, Lionel M.L. Chow

Bibliographic record

VenueOncotarget · 2018
Typearticle
Languageen
FieldMedicine
TopicVascular Tumors and Angiosarcomas
Canadian institutionsMontreal Clinical Research Institute
FundersCanadian Institutes of Health ResearchNational Heart, Lung, and Blood InstituteSontag Foundation
KeywordsPI3K/AKT/mTOR pathwayCancer researchAngiosarcomaMedicinePTENContext (archaeology)CancerPathologyBiologyApoptosisInternal medicine

Abstract

fetched live from OpenAlex

// Michelle L. Chadwick 1, 2 , Adam Lane 2 , Dana Thomas 2 , Amanda R. Smith 2 , Angela R. White 2 , Dominique Davidson 3 , Yuxin Feng 2 , Elisa Boscolo 2 , Yi Zheng 1, 2 , Denise M. Adams 4 , Anita Gupta 5 , André Veillette 3 and Lionel M.L. Chow 1, 2 1 Department of Cancer and Cell Biology, University of Cincinnati, Cincinnati, OH, USA 2 Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA 3 Institut de Recherches Cliniques de Montréal, Montréal, Canada 4 Vascular Anomalies Center, Boston Children’s Hospital, Boston, MA, USA 5 Department of Pathology and Laboratory Medicine, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA Correspondence to: Lionel M.L. Chow, email: lionel.chow@cchmc.org Keywords: angiosarcoma; mouse model; pre-clinical therapeutics; mTOR; MEK Received: March 09, 2018 Accepted: April 21, 2018 Published: May 15, 2018 ABSTRACT Angiosarcoma is an aggressive malignancy of vascular origin that occurs de novo or in the context of previous cancer therapy. Despite multi-modal aggressive treatment including surgical resection, chemotherapy, and radiation, five-year overall survival remains poor at 35%. Due to its rarity, little is known about its molecular pathology and clinical trials have been extremely difficult to conduct. Development of animal models for rare diseases like angiosarcoma is critical to improve our understanding of tumorigenesis and to test novel treatment regimens. A genetically engineered mouse model for angiosarcoma was generated by conditional deletion of Trp53 , Pten , and Ptpn12 in endothelial cells. Tumors arising from these mice recapitulate the histology and molecular pathology of the human disease including hyperactivation of the PI3K/mTOR and MAPK signaling pathways. Treatment of tumor-bearing mice with mTOR or MEK inhibitors effectively inactivated signaling and resulted in reduced proliferation and elevated apoptosis leading to tumor regression. The effect of treatment on tumor growth was transient and proliferation was restored after a period of dormancy. However, combined inhibition of mTOR and MEK resulted in profound tumor regression which was sustained for the duration of treatment. These results suggest that angiosarcoma may be effectively treated by this drug combination.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.001
Open science0.0000.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.025
GPT teacher head0.288
Teacher spread0.262 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations27
Published2018
Admission routes3
Has abstractyes

Explore more

Same venueOncotargetSame topicVascular Tumors and AngiosarcomasFrench-language works237,207